Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FSCD7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,582
Award facts
- Contract value 100% obligated
- $29,581.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi (ruxolitinib) 10 mg tablets in a quantity of 60 units. This firm fixed-price delivery order, valued at $29,581.90 with an ultimate completion date of January 15, 2026, was awarded without set-aside designation on January 14, 2026. The award leverages DMS Pharmaceutical Group's position as a regional prime vendor contractor under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract (SPE2DR) under the PPV-G GEN V program, awarded in November 2025 with a $499.9 million ceiling value and completion date of December 31, 2036. The company's established performance across numerous delivery orders spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals demonstrates its capability to support the diverse medical supply requirements of military healthcare operations. This delivery order for Jakafi, a specialty pharmaceutical used in hematologic malignancies and inflammatory conditions, exemplifies the routine procurement activity enabled under the broader prime vendor contract structure.
Quick answers
Who was awarded contract SPE2DR26FSCD7?
SPE2DR26FSCD7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FSCD7 worth?
The government has obligated $29,582 on SPE2DR26FSCD7.
Is contract SPE2DR26FSCD7 an order under another contract?
Yes. SPE2DR26FSCD7 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCD7 competed?
The extent of competition for SPE2DR26FSCD7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award